Optimizing ceftazidime dosing in the ICU
Part of Infections clinical trials.
This trial tests if adjusting ceftazidime (a powerful antibiotic) early on helps treat serious infections better in intensive care patients. You may qualify if you are in the ICU and your doctor is considering starting this antibiotic.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in the intensive care unit (ICU) and expected to stay at least 3 days.
- You have an infection that might be treated with the antibiotic ceftazidime.
- You have an arterial line (a small tube in an artery) for blood draws.
- You are covered by a social security plan or similar health insurance.
- You are not pregnant, breastfeeding, or a new mother.
- You are not under legal guardianship or unable to give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial measures how ceftazidime (an antibiotic) moves through the body and how it works in children with severe infections in the pediatric intensive care unit. It may help doctors choose safer, more effective dosing for kids.
This trial tests a way to give the antibiotic cefepime to ICU patients. It aims to see if the dosing can be adjusted more precisely for each person.
This trial checks if giving higher doses of beta-lactam antibiotics (a type of strong antibiotic) right from the start helps people in the ICU with septic shock. It aims to find the best dose to fight the infection quickly.
This trial tests whether giving a certain type of antibiotic (beta-lactam) continuously or intermittently works better for patients in the intensive care unit with pneumonia or a urinary tract infection and signs of sepsis. Sepsis is a serious response to an infection, so better antibiotic delivery could improve outcomes.
This trial tests whether using a blood test called 'PCT' can help doctors decide when to start or stop antibiotics in critically ill adult patients in the EICU. The goal is to reduce unnecessary antibiotic use while still effectively treating bacterial infections.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
Hear when a new Infection in ICU trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.